Next Article in Journal
Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression
Next Article in Special Issue
Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
Previous Article in Journal
The Multifunctionality of CD36 in Diabetes Mellitus and Its Complications—Update in Pathogenesis, Treatment and Monitoring
Previous Article in Special Issue
Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations
Perspective

The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease

The Michael J. Fox Foundation for Parkinson’s Research, Grand Central Station, P.O. Box 4777, New York, NY 10120, USA
*
Authors to whom correspondence should be addressed.
Cells 2020, 9(8), 1878; https://doi.org/10.3390/cells9081878
Received: 11 July 2020 / Revised: 1 August 2020 / Accepted: 7 August 2020 / Published: 11 August 2020
(This article belongs to the Special Issue LRRK2-Dependent Neurodegeneration in Parkinson’s Disease)
Since 2005, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has invested significant funding and non-funding effort to accelerate research and drug development activity around the Parkinson disease (PD)-associated protein LRRK2. MJFF has spearheaded multiple public/private pre-competitive collaborations that have contributed to our understanding of LRRK2 function; de-risked potential safety questions around the therapeutic use of LRRK2 kinase inhibitors; and generated critical research tools, biosamples, and data for the field. Several LRRK2-targeted therapies are now in human testing due to the hard work of so many in the PD community. In this perspective, we present a holistic description and model of how our Foundation’s support targeted important barriers to LRRK2 research and helped move the field into clinical trials. View Full-Text
Keywords: Parkinson disease; genetic; therapeutic development; Rab; Collaboration; LRRK2; biomarkers; antibodies Parkinson disease; genetic; therapeutic development; Rab; Collaboration; LRRK2; biomarkers; antibodies
Show Figures

Figure 1

MDPI and ACS Style

Padmanabhan, S.; Fiske, B.K.; Baptista, M.A.S. The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. Cells 2020, 9, 1878. https://doi.org/10.3390/cells9081878

AMA Style

Padmanabhan S, Fiske BK, Baptista MAS. The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. Cells. 2020; 9(8):1878. https://doi.org/10.3390/cells9081878

Chicago/Turabian Style

Padmanabhan, Shalini, Brian K. Fiske, and Marco A.S. Baptista 2020. "The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease" Cells 9, no. 8: 1878. https://doi.org/10.3390/cells9081878

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop